LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

18.54 0.87

Buy Sell

Overview

Share price change

24h

Current

Min

18.12

Max

18.76

Key metrics
By Trading Economics
Income	-607K -51M
Sales	-28M 100M
EPS	-0.46
Profit margin	-51.215
Employees	1,784
EBITDA	4.1M -44M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+75.61% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-308M 2.1B
Previous open	17.67
Previous close	18.54

News Sentiment

By Acuity

30%

70%

59 / 344 Ranking in Healthcare

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 maj 2026, 21:33 UTC

Earnings

Correction to Salesforce 1Q Sales, Profit Rise Article

27 maj 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 maj 2026, 20:18 UTC

Earnings

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 maj 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 maj 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 maj 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 maj 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 maj 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 maj 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 maj 2026, 21:29 UTC

Hot Stocks

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 maj 2026, 21:08 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 maj 2026, 21:02 UTC

Earnings

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 maj 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 maj 2026, 20:55 UTC

Earnings

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 maj 2026, 20:48 UTC

Earnings

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 maj 2026, 20:45 UTC

Earnings

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 maj 2026, 20:34 UTC

Acquisitions, Mergers, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 maj 2026, 20:32 UTC

Earnings

Acquisitions, Mergers, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 maj 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 maj 2026, 20:32 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 maj 2026, 20:30 UTC

Earnings

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 maj 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 maj 2026, 20:22 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 maj 2026, 20:16 UTC

Earnings

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 maj 2026, 20:13 UTC

Earnings

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 maj 2026, 20:13 UTC

Earnings

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 maj 2026, 20:13 UTC

Earnings

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 maj 2026, 20:12 UTC

Earnings

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 maj 2026, 20:12 UTC

Earnings

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

75.61% upside

12 Months Forecast

Average 32.4 USD 75.61%

High 44 USD

Low 21.6 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Sentiment

By Acuity

59 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.